Materialise (MTLS) Q4 2025 earnings review
Medical Engine Powers Q4 Turnaround
After three quarters of stagnation or decline, Materialise returned to growth in Q4 with revenue up 6.8% YoY to €70.2M. The story remains a sharp dichotomy: the Medical segment is booming (+16% YoY, 35% EBITDA margins), while the industrial side (Manufacturing and Software) continues to shrink, albeit at a slower pace. Profitability surged—Net Income more than doubled to €6.2M—driven by a favorable mix shift toward high-margin Medical revenue and strict cost discipline. Management's FY26 guidance projects a return to full-year growth (€273-283M), signaling that the worst of the industrial destocking may be over.
🐂 Bull Case
The Medical segment now accounts for over 50% of revenue and is accelerating (Q4 +16.3% vs FY +15.4%). With 35.2% Adjusted EBITDA margins, this segment provides a massive profitability buffer while industrial segments stabilize.
Despite mixed top-line results, Adjusted EBITDA jumped 121% YoY in Q4 (€9.5M vs €4.3M). Gross margins expanded to 58.1%, proving the company can expand earnings even with muted industrial demand.
🐻 Bear Case
The Manufacturing segment remains a drag, shrinking 2.4% YoY. More concerning is the profitability: Adjusted EBITDA margin was -9.9%. While 'less bad' than last year (-13.2%), this segment is still burning cash.
Software revenue declined 1.3% YoY. While management points to a transition to subscription models, the segment has struggled to show headline growth for the entire fiscal year (-6.8% FY25).
⚖️ Verdict: 🟢
Bullish. The return to consolidated growth and the doubling of Net Income validate the 'Medical-first' thesis. While Manufacturing remains a headache, the bleeding has slowed, and the company's strong cash position (€134M) + buyback announcement signals management confidence.
Key Themes
Medical Segment Dominance
Medical is not just growing; it is carrying the entire P&L. Revenue hit €37.0M (+16.3% YoY), and Adjusted EBITDA margin expanded to 35.2% from 30.0%. This segment now generates more EBITDA (€13.0M) than the entire consolidated group (€9.5M), effectively subsidizing the losses in Manufacturing.
Manufacturing Profitability Hole
The Manufacturing segment posted an Adjusted EBITDA loss of €2.2M (margin -9.9%). Management cited 'soft prototyping demand' and a shift toward series manufacturing. While the strategic shift to aerospace/defense is logical, the legacy business is deteriorating faster than new verticals are ramping.
Euronext Listing & Buybacks
The quarter included costs for a Euronext listing (€0.75M) and the announcement of a strategic share buyback program. With €134M in cash and net cash increasing by nearly €10M in the quarter, capital allocation is shifting toward shareholder returns.
Operational Leverage
Gross profit grew 12.2% YoY, twice the rate of revenue growth (6.8%). OpEx remained flat (€38.9M vs €39.0M YoY) despite inflation and listing costs. This operational discipline allowed a modest top-line beat to translate into a massive bottom-line improvement.
Software Growth Stalled
Software revenue fell 1.3% YoY to €11.0M. While management argues this is due to a business model transition (cloud/subscription), the segment has shown negative growth for the full year (-6.8%). A return to growth in this high-margin vertical is critical for FY26.
Macro Headwinds Persist
Management noted that the industrial market segments will continue to face 'macroeconomic headwinds' throughout 2026. This suggests the Manufacturing segment's recovery will be slow and grindy rather than a sharp V-shaped bounce.
Other KPIs
Up from €102.3M a year ago. Net cash position improved to €70.8M. This fortress balance sheet allows for the newly announced buyback program without compromising R&D.
Accelerating. More than double the €4.3M reported in 24Q4. The margin expansion to 13.6% (vs 6.6% prior year) confirms the effectiveness of cost control measures.
Stable. Generated positive free cash flow for the full year, despite significant CAPEX (€16.3M). Q4 alone contributed €4.5M in FCF.
Guidance
Accelerating. Implies ~2% to 5.7% growth vs FY25 (€267.6M). This marks a pivot from the flat performance of 2025, driven largely by continued Medical strength.
Stable/Slight Growth. Compared to FY25 Adjusted EBIT of €10.6M. The midpoint implies modest operational leverage, likely constrained by continued losses in Manufacturing.
Key Questions
Manufacturing Breakeven
Manufacturing Adjusted EBITDA margin was -9.9% in Q4. What is the specific revenue level or timeline required to get this segment back to breakeven?
Software Transition Timeline
Software revenue has declined for the full year. When does the subscription transition cross the inflection point where reported revenue returns to growth?
Capital Allocation
With €134M in cash and a new buyback program, how aggressive will the buybacks be, and does this signal a lack of M&A targets in the near term?